What does others — financial royalty assets, allowance mean?

This metric reflects the cumulative valuation adjustments or reserves established against the gross carrying value of royalty assets within the 'Others' segment. It accounts for potential impairments, credit risks, or changes in the expected recoverability of future royalty streams associated with these specific licensed technologies. An increase in this allowance typically signals management's assessment of heightened risk or diminished commercial prospects for the underlying drug programs.

Ligand Pharmaceuticals (LGND) Others — Financial Royalty Assets, Allowance

Screener

Other product segments

Qarziba

$468K—

Similar metrics at other companies

RPRXCash collections from financial royalty assets

$814.85M+12.2%

RPRXCash collections from financial royalty assets

$814.85M+12.2%

RPRXCash collections from financial royalty assets

$814.85M+12.2%

RPRXIncome from financial royalty assets — Total income and other revenues

$638.03M+15.9%

BCRXRoyalty Financing Liabilities

$426.79M-11.7%

BCRXRoyalty financing obligations

$43.81M+22.6%

Other financials

Income statement

See full

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

See full

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

See full

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

See full

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

See full

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

See full

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:06 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000886163-26-000044

Line item	June 30, 2026 / Gross carrying value(1)	June 30, 2026 / Allowance	June 30, 2026 / Net carrying value (1)	December 31, 2025 / Gross carrying value(1)	December 31, 2025 / Allowance	December 31, 2025 / Net carrying value(1)
Tolerance Therapeutics (Tzield®)	25,470	(99)	25,371	25,257	(98)	25,159
Ohtuvayre inventors	19,957	(179)	19,778	16,921	(151)	16,770
Elutia (CorMatrix)	6,062	(837)	5,225	6,607	(1,107)	5,500
AT220	4,442	(109)	4,333	5,132	(132)	5,000
Primrose mRNA	3,281	(98)	3,183	3,281	(98)	3,183
Zerion	2,640	(79)	2,561	—	—	—
Others	5,729	(212)	5,517	5,769	(214)	5,555
Total financial royalty assets, net	$209,699	$(2,489)	$207,210	$222,375	$(2,706)	$219,669

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's others — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported others — financial royalty assets, allowance of $212K in Q2 2026.
What does others — financial royalty assets, allowance mean?: This metric reflects the cumulative valuation adjustments or reserves established against the gross carrying value of royalty assets within the 'Others' segment. It accounts for potential impairments, credit risks, or changes in the expected recoverability of future royalty streams associated with these specific licensed technologies. An increase in this allowance typically signals management's assessment of heightened risk or diminished commercial prospects for the underlying drug programs.